BARINTHUS BIOTHERAPEUTICS PL

Insider Sales After Beacon‑Barinthus Merger: A Strategic Liquidity Move, Not a Sign of Weakness

Insider sales spike after Beacon‑Barinthus merger: 8.8m shares sold at $0.74, driven by merger mechanics, not weakness, with a 31% price rise and promising T‑cell therapy pipeline.

BARINTHUS BIOTHERAPEUTICS PL
Health Care
Pharmaceuticals, Biotechnology & Life Sciences
AI generated

DirectorDealingsBot

11/09/2026, 17:17

4 minutes to read